Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
WILMINGTON, Del.—Krishna Vaddi, CEO of Prelude Therapeutics Inc . (NASDAQ:PRLD), has expanded his holdings in the company through recent stock acquisitions, showing confidence despite the stock trading near its 52-week low of $0.66. According to the latest SEC filing, Vaddi purchased a total of 39,105 shares of the company’s common stock in two transactions dated March 14 and March 17, 2025. The acquisitions were made at an average price range of $0.7499 to $0.7544 per share, amounting to a total investment of $29,459. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report.
Following these transactions, Vaddi’s direct ownership in Prelude Therapeutics increased to 1,303,880 shares. Additionally, Vaddi holds indirect ownership interests through various trusts, bringing his total indirect holdings to 1,669,758 shares. The company maintains strong liquidity with a current ratio of 5.3, indicating solid short-term financial health.
Prelude Therapeutics, headquartered in Wilmington, Delaware, is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. With a market capitalization of $38.66 million, the company has shown recent momentum with a 14% gain over the past week. For deeper insights into insider trading patterns and comprehensive financial analysis, visit InvestingPro, where you’ll find 12 additional ProTips and detailed valuation metrics.
In other recent news, Prelude Therapeutics reported its fourth-quarter 2024 financial results, revealing a strong cash position of $133.6 million. JMP Securities reiterated its Market Outperform rating for the company, maintaining a $4.00 price target. The firm’s analysts noted the modest efficacy of Prelude’s PRT3789 in initial monotherapy results, emphasizing its potential as a combination therapy. Prelude Therapeutics has two assets advancing through clinical trials, with particular interest in the objective responses from patients with upper gastrointestinal tract tumors treated with PRT3789. Analysts at JMP Securities are looking forward to further data expected in the second half of 2025, which will aid in reassessing market models. They view the company’s stock as presenting a distinct investment opportunity, with potential scenarios ranging from a downside of $0 to an upside of $5 per share. The current outlook for Prelude Therapeutics is positive, as analysts anticipate additional results from a larger patient cohort.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.